Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Impact of new medications on the treatment of immune TTP

Marie Scully, Lara Howells, William A. Lester

Blood (2025) 145 (13): 1353–1357.

https://doi.org/10.1182/blood.2024026390

Published: 2025

Journal Articles

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

Constantine S. Tam, Shalini Balendran, Piers Blombery

Blood (2025) 145 (10): 1005–1009.

https://doi.org/10.1182/blood.2024026672

Published: 2025

Journal Articles

FDA-approved therapies for chronic GVHD

Stephanie J. Lee, Robert Zeiser

Blood (2025) 145 (8): 795–800.

https://doi.org/10.1182/blood.2024026633

Published: 2025

Journal Articles

Menin inhibitors in the treatment of acute myeloid leukemia

Gerwin Huls, Carolien M. Woolthuis, Jan Jacob Schuringa

Blood (2025) 145 (6): 561–566.

https://doi.org/10.1182/blood.2024026232

Published: 2025

Journal Articles

Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS

Yasmin Abaza, Amy E. DeZern

Blood (2025) 145 (5): 469–474.

https://doi.org/10.1182/blood.2024025702

Published: 2025

Includes: Supplemental data

Journal Articles

Building the future management of follicular lymphoma with T-cell–redirecting strategies

Gloria Iacoboni, Franck Morschhauser

Blood (2025) 145 (2): 170–175.

https://doi.org/10.1182/blood.2024025699

Published: 2025

Includes: Supplemental data

Journal Articles

Momelotinib for the treatment of myelofibrosis

Prithviraj Bose

Blood (2024) 144 (7): 708–713.

https://doi.org/10.1182/blood.2023023719

Published: 2024

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Edward J. Benz, Jr., Leslie E. Silberstein, Julie Panepinto

Blood (2024) 143 (11): 967–970.

https://doi.org/10.1182/blood.2023021598

Published: 2024

Journal Articles

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

Dina S. Parekh, William A. Eaton, Swee Lay Thein

Blood (2024) 143 (10): 866–871.

https://doi.org/10.1182/blood.2023021167

Published: 2024

Journal Articles

CAR T-cell therapy in multiple myeloma: mission accomplished?

Leo Rasche, Michael Hudecek, Hermann Einsele

Blood (2024) 143 (4): 305–310.

https://doi.org/10.1182/blood.2023021221

Published: 2024

Journal Articles

Macrophage heterogeneity in the single-cell era: facts and artifacts

David A. Hume, Susan M. Millard, Allison R. Pettit

Blood (2023) 142 (16): 1339–1347.

https://doi.org/10.1182/blood.2023020597

Published: 2023

Journal Articles

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Philip A. Thompson, Constantine S. Tam

Blood (2023) 141 (26): 3137–3142.

https://doi.org/10.1182/blood.2023020240

Published: 2023

Includes: Supplemental data

Journal Articles

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella

Blood (2023) 141 (18): 2187–2193.

https://doi.org/10.1182/blood.2022016590

Published: 2023

Journal Articles

Vaccine-induced immune thrombotic thrombocytopenia

Douglas B. Cines, Andreas Greinacher

Blood (2023) 141 (14): 1659–1665.

https://doi.org/10.1182/blood.2022017696

Published: 2023

Journal Articles

Minimal information for reporting a genomics experiment

Kostiantyn Dreval, Paul C. Boutros, Ryan D. Morin

Blood (2022) 140 (24): 2549–2555.

https://doi.org/10.1182/blood.2022016095

Published: 2022

Includes: Supplemental data

Journal Articles

MRD in multiple myeloma: does CR really matter?

Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau

Blood (2022) 140 (23): 2423–2428.

https://doi.org/10.1182/blood.2022016170

Published: 2022

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Florence Vallelian, Paul W. Buehler, Dominik J. Schaer

Blood (2022) 140 (17): 1837–1844.

https://doi.org/10.1182/blood.2022015596

Published: 2022

Journal Articles

Avapritinib for advanced systemic mastocytosis

Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo

Blood (2022) 140 (15): 1667–1673.

https://doi.org/10.1182/blood.2021014612

Published: 2022

NARROW

Impact of new medications on the treatment of immune TTP

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

FDA-approved therapies for chronic GVHD

Menin inhibitors in the treatment of acute myeloid leukemia

Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS

Building the future management of follicular lymphoma with T-cell–redirecting strategies

Momelotinib for the treatment of myelofibrosis

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

CAR T-cell therapy in multiple myeloma: mission accomplished?

Macrophage heterogeneity in the single-cell era: facts and artifacts

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Vaccine-induced immune thrombotic thrombocytopenia

Minimal information for reporting a genomics experiment

MRD in multiple myeloma: does CR really matter?

Daratumumab in AL amyloidosis

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Avapritinib for advanced systemic mastocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only